anti-Olfactomedin 4 (OLFM4) Antibodies

Human Olfactomedin 4 (OLFM4) interaction partners

1. Study results suggest that OLFM4, LY6D and S100A7 immunoreactivity are associated with an aggressive phenotype of estrogen receptor (ER)-positive breast carcinoma, and these are potent markers for distant metastasis of ER-positive breast cancer patients.

2. these data propose that hCG is not a key regulator of cellular alterations within peripheral blood dendritic cells

3. discovered that OLFM4, CD11b, and ITGA2 are proteins that are overexpressed in both primary colon tumors and liver metastasis. These are colon cancer biomarkers with autoantigenic properties.

4. MiR-103 acts as an oncogene miRNA to promote triple-negative breast cancer cells migration and invasion through targeting OLFM4.

5. OLFM4 has an important role in the regulation of intestinal inflammation and tumorigenesis, and could be a potential therapeutic target for intestinal malignant tumors. Unlike the human colonic epithelium, the mouse colonic epithelium does not express OLFM4, but nevertheless, systemic OLFM4 deletion promotes colon tumorigenesis and that loss from mucosal neutrophils may have a role to play.

6. Olfactomedin-4 identifies a subpopulation of neutrophils in patients with septic shock, and those with a high percentage of olfactomedin-4+ neutrophils are at higher risk for greater organ failure burden and death. Olfactomedin-4 might serve as a marker of a pathogenic neutrophil subset in patients with septic shock

7. OLFM4 is proved to as a functional target for miR-590.

8. Olfactomedin 4 is a novel tumor marker for triple-negative breast cancer for predicting and prognosis.

9. OLFM4 is downregulated by miR-486-5p, which contributes to ovarian cancer tumorigenesis. Conversely, estrogen receptor signaling downregulates miR-486-5p and upregulates OLFM4 expression, slowing the development and progression of ovarian cancer.

10. Data show that olfactomedin 4 (OLFM4) is highly expressed in proliferating benign epithelial cells and in some carcinoma cells.

11. olfactomedin 4 appears to play a critical role in regulating progression of prostate cancer, and has potential as a new biomarker for prostate cancer.

12. Study demonstrates that epigenetic silencing of OLFM4 enhances gastric cancer cell invasion via activation of FAK signaling.

13. suppression of OLFM4 expression may be a promising strategy in the development of novel cancer therapeutic drugs

14. Patients with an OLFM4 gene expression level above -7.5 were 6 times more likely to develop severe disease, after correction for age at hospitalization and gestational age.

15. Using a human vaginal epithelial cell line, the expression of mucin 5 subtype B and olfactomedin-4 were down-regulated in response to N9, suggesting these markers could apply to humans

16. findings suggest that OLFM4 is not only involved in early stages of gastric carcinogenesis but also a useful prognostic marker for advanced gastric cancer

17. OLM4 expression is increased in the early stages of gastric, colorectal, and pancreatic cancer initiation.

18. High expression of GW112 in colorectal cancer tissues and reduced expression of GRIM-19 in colorectal cancer tissues may be associated with abnormal proliferation of cancer cells.

19. although low OLFM4 expression is not an independent prognostic biomarker, it might indicate worse prognosis for smoking patients with non-small cell lung cancer

20. Impairment of ERalpha signal-mediated OLFM4 expression promoted the malignant progression of endometrioid adenocarcinoma.

Mouse (Murine) Olfactomedin 4 (OLFM4) interaction partners

1. Olfm4 contributes to H2O2-induced NADPH oxidase activation.

2. Studies suggest that Olfm4 negatively regulates glucose-stimulated insulin secretion.

3. OLFM4 has an important role in the regulation of intestinal inflammation and tumorigenesis, and could be a potential therapeutic target for intestinal malignant tumors. Unlike the human colonic epithelium, the mouse colonic epithelium does not express OLFM4, but nevertheless, systemic OLFM4 deletion promotes colon tumorigenesis and that loss from mucosal neutrophils may have a role to play.

4. olfactomedin 4 appears to play a critical role in regulating progression of prostate cancer, and has potential as a new biomarker for prostate cancer.

5. OLFM4 may function as a tumor suppressor and an anti-metastatic gene during tumor progression

6. Olfm4 deletion can successfully enhance immune defense against S. aureus, but not A. fumigatus, in chronic granulomatous disease mice.

7. OLFM4 exerts considerable influence on the host defense against H. pylori infection acting through NOD1 and NOD2 mediated NF-kappaB activation and subsequent cytokines and chemokines production, which in turn inhibit host immune response.

8. a novel PU.1-regulated extracellular glycoprotein of the olfactomedin-like family has a possible role in neutrophilic trafficking.(pdp4)